Jian Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jian Hu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Aifeng Wang
Department of Pediatrics, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University
1 shared publicationBingrui Yu
Department of Neonatology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, China
1 shared publicationChunlin Gao
Department of Pediatrics, Jinling Hospital, Nanjing, Jiangsu 210002, China.
1 shared publicationHaiyan Zhu
Department of Pediatrics, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, China
1 shared publication- Haiyan Zhu
Department of Pediatrics, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, China
1 shared publication Jingyan Li
Department of Neonatology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, China
1 shared publication
Latest Publications
- Open Access
- 1 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1809178
CCR1+ monocytes facilitating bronchopulmonary dysplasia through regulation of S100A8 and MMP8
Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease in preterm infants and is characterized by aberrant late-stage lung development driven by multiple factors. Although previous studies have demonstrated that BPD is associated with prenatal and postnatal inflammatory stimuli, the inflammatory mechanisms involved immune cell populations have not been fully elucidated. Here, we systematically investigated the roles of myeloid cells in the inflammatory processes underlying BPD. Using single-cell transcriptomic data of normal and BPD mouse lung, we found that the proportions of several myeloid subpopulations were specifically upregulated in BPD lung, including CCR1 + monocytes, CD74 + macrophages, IL7R + macrophages, MARCO + macrophages, CD63 + neutrophils, and CD73 + neutrophils. However, we only validated the increased proportions of CCR1 + monocytes in human BPD blood through flow cytometry analysis. Combined with bulk transcriptome and detection in serum of human BPD blood, we identified S100A8 and MMP8 as highly expressed downstream factors of CCR1 + monocytes. Immunofluorescence staining further confirmed the presence of CCR1 + monocytes expressing S100A8 or MMP8 in the mouse BPD lung tissues and demonstrated their association with disease development. Finally, in CCR1 + monocytes isolated from the peripheral blood of BPD infants, we found that the NF-κB and AKT pathways regulate the production of S100A8 and MMP8 respectively. Our study explored the role and mechanism of CCR1 + monocytes associated with BPD, which offers valuable insights for the development of novel clinical biomarkers and therapeutic strategies for BPD.
- 1 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1809178
Open AccessCCR1+ monocytes facilitating bronchopulmonary dysplasia through regulation of S100A8 and MMP8
Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease in preterm infants and is characterized by aberrant late-stage lung development driven by multiple factors. Although previous studies have demonstrated that BPD is associated with prenatal and postnatal inflammatory stimuli, the inflammatory mechanisms involved immune cell populations have not been fully elucidated. Here, we systematically investigated the roles of myeloid cells in the inflammatory processes underlying BPD. Using single-cell transcriptomic data of normal and BPD mouse lung, we found that the proportions of several myeloid subpopulations were specifically upregulated in BPD lung, including CCR1 + monocytes, CD74 + macrophages, IL7R + macrophages, MARCO + macrophages, CD63 + neutrophils, and CD73 + neutrophils. However, we only validated the increased proportions of CCR1 + monocytes in human BPD blood through flow cytometry analysis. Combined with bulk transcriptome and detection in serum of human BPD blood, we identified S100A8 and MMP8 as highly expressed downstream factors of CCR1 + monocytes. Immunofluorescence staining further confirmed the presence of CCR1 + monocytes expressing S100A8 or MMP8 in the mouse BPD lung tissues and demonstrated their association with disease development. Finally, in CCR1 + monocytes isolated from the peripheral blood of BPD infants, we found that the NF-κB and AKT pathways regulate the production of S100A8 and MMP8 respectively. Our study explored the role and mechanism of CCR1 + monocytes associated with BPD, which offers valuable insights for the development of novel clinical biomarkers and therapeutic strategies for BPD.
- 24 July 2024
- Published by Springer Nature in Inflammation
- Vol. 48 (2) , 796-805
Interleukin-11 Is Involved in Hyperoxia-induced Bronchopulmonary Dysplasia in Newborn Mice by Mediating Epithelium-Fibroblast Cross-talk
Background: Bronchopulmonary dysplasia (BPD) is a chronic lung disorder predominantly affecting preterm infants. Oxygen therapy, a common treatment for BPD, often leads to hyperoxia-induced pulmonary damage, particularly targeting alveolar epithelial cells (AECs). Crucially, disrupted lung epithelium-fibroblast interactions significantly contribute to BPD's pathogenesis. Previous studies on interleukin-11 (IL-11) in lung diseases have yielded conflicting results. Recent research, however, highlights IL-11 as a key regulator of fibrosis, stromal inflammation, and epithelial dysfunction. Despite this, the specific role of IL-11 in BPD remains underexplored. Our transcriptome analysis of normal and hyperoxia-exposed murine lung tissues revealed an increased expression of IL-11 RNA. This study aimed to investigate IL-11's role in modulating the disrupted interactions between AECs and fibroblasts in BPD. Methods: BPD was modeled in vivo by exposing C57BL/6J neonatal mice to hyperoxia. Histopathological changes in lung tissue were evaluated with hematoxylin-eosin staining, while lung fibrosis was assessed using Masson staining and immunohistochemistry (IHC). To investigate IL-11's role in pulmonary injury contributing to BPD, IL-11 levels were reduced through intraperitoneal administration of IL-11RαFc in hyperoxia-exposed mice. Additionally, MLE-12 cells subjected to 95% oxygen were collected and co-cultured with mouse pulmonary fibroblasts (MPFs) to measure α-SMA and Collagen I expression levels. IL-11 levels in the supernatants were quantified using an enzyme-linked immunosorbent assay (ELISA). Results: Both IHC and Masson staining revealed that inhibiting IL-11 expression alleviated pulmonary fibrosis in neonatal mice induced by hyperoxia, along with reducing the expression of fibrosis markers α-SMA and collagen I in lung tissue. In vitro analysis showed a significant increase in IL-11 levels in the supernatant of MLE-12 cells treated with hyperoxia. Silencing IL-11 expression in MLE-12 cells reduced α-SMA and collagen I concentrations in MPFs co-cultured with the supernatant of hyperoxia-treated MLE-12 cells. Additionally, ERK inhibitors decreased α-SMA and collagen I levels in MPFs co-cultured with the supernatant of hyperoxia-treated MLE-12 cells. Clinical studies found increased IL-11 levels in tracheal aspirates (TA) of infants with BPD. Conclusion: This research reveals that hyperoxia induces IL-11 secretion in lung epithelium. Additionally, IL-11 derived from lung epithelium emerged as a crucial mediator in myofibroblast differentiation via the ERK signaling pathway, highlighting its potential therapeutic value in BPD treatment.
- 24 July 2024
- Published by Springer Nature in Inflammation
- Vol. 48 (2) , 796-805
Interleukin-11 Is Involved in Hyperoxia-induced Bronchopulmonary Dysplasia in Newborn Mice by Mediating Epithelium-Fibroblast Cross-talk
Background: Bronchopulmonary dysplasia (BPD) is a chronic lung disorder predominantly affecting preterm infants. Oxygen therapy, a common treatment for BPD, often leads to hyperoxia-induced pulmonary damage, particularly targeting alveolar epithelial cells (AECs). Crucially, disrupted lung epithelium-fibroblast interactions significantly contribute to BPD's pathogenesis. Previous studies on interleukin-11 (IL-11) in lung diseases have yielded conflicting results. Recent research, however, highlights IL-11 as a key regulator of fibrosis, stromal inflammation, and epithelial dysfunction. Despite this, the specific role of IL-11 in BPD remains underexplored. Our transcriptome analysis of normal and hyperoxia-exposed murine lung tissues revealed an increased expression of IL-11 RNA. This study aimed to investigate IL-11's role in modulating the disrupted interactions between AECs and fibroblasts in BPD. Methods: BPD was modeled in vivo by exposing C57BL/6J neonatal mice to hyperoxia. Histopathological changes in lung tissue were evaluated with hematoxylin-eosin staining, while lung fibrosis was assessed using Masson staining and immunohistochemistry (IHC). To investigate IL-11's role in pulmonary injury contributing to BPD, IL-11 levels were reduced through intraperitoneal administration of IL-11RαFc in hyperoxia-exposed mice. Additionally, MLE-12 cells subjected to 95% oxygen were collected and co-cultured with mouse pulmonary fibroblasts (MPFs) to measure α-SMA and Collagen I expression levels. IL-11 levels in the supernatants were quantified using an enzyme-linked immunosorbent assay (ELISA). Results: Both IHC and Masson staining revealed that inhibiting IL-11 expression alleviated pulmonary fibrosis in neonatal mice induced by hyperoxia, along with reducing the expression of fibrosis markers α-SMA and collagen I in lung tissue. In vitro analysis showed a significant increase in IL-11 levels in the supernatant of MLE-12 cells treated with hyperoxia. Silencing IL-11 expression in MLE-12 cells reduced α-SMA and collagen I concentrations in MPFs co-cultured with the supernatant of hyperoxia-treated MLE-12 cells. Additionally, ERK inhibitors decreased α-SMA and collagen I levels in MPFs co-cultured with the supernatant of hyperoxia-treated MLE-12 cells. Clinical studies found increased IL-11 levels in tracheal aspirates (TA) of infants with BPD. Conclusion: This research reveals that hyperoxia induces IL-11 secretion in lung epithelium. Additionally, IL-11 derived from lung epithelium emerged as a crucial mediator in myofibroblast differentiation via the ERK signaling pathway, highlighting its potential therapeutic value in BPD treatment.
- Open Access
- 27 May 2024
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 70 (5) , 284-288
A novel gain-of-function mutation in Transient Receptor Potential C6 that causes podocytes injury
Podocyte injury plays a vital role in focal segmental glomerulosclerosis (FSGS), and apoptosis is one of its mechanisms. The transient receptor potential channel 6 (TRPC6) is highly expressed in podocytes and mutations mediate podocyte injury. We found TRPC6 gene mutation (N110S) was a new mutation and pathogenic in the preliminary clinical work. The purpose of this study was to investigate the potential mechanism of mutation in TRPC6 (TRPC6-N110S) in the knock-in gene mouse model and in immortalized mouse podocytes (MPC5). Transmission electron microscopy was used to evaluate renal injury morphology. We measured 24-hour urinary albumin-to-creatinine ratios and major biochemical parameters such as serum albumin, urea nitrogen, and total cholesterol. The results of CCK-8 assay and apoptosis experiments showed that the TRPC6-N110S overexpression group had slower proliferative activity and increased apoptosis than the control group. FluO-3 assay revealed increased calcium influx in the TRPC6-N110S overexpression group. Podocin level was decreased in TRPC6-N110S group, while TRPC6 and desmin levels were increased in TRPC6-N110S group. The 24 h uACR at 6 weeks was significantly higher in the pure-zygotes group than in the WT and heterozygotes groups, and this difference was found at 8 and 10 weeks.TRPC6 levels showed no significant difference between homozygote and WT mice. Compared to homozygote group, expression of podocin and nephrin were increased in WT, but levels of desmin was decreased in WT. Our results suggest that this new mutation causes podocyte injury probably by enhancing calcium influx and podocyte apoptosis, accompanied by increased proteinuria and decreased expression of nephrin and podocin.
- 27 May 2024
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 70 (5) , 284-288
Open AccessA novel gain-of-function mutation in Transient Receptor Potential C6 that causes podocytes injury
Podocyte injury plays a vital role in focal segmental glomerulosclerosis (FSGS), and apoptosis is one of its mechanisms. The transient receptor potential channel 6 (TRPC6) is highly expressed in podocytes and mutations mediate podocyte injury. We found TRPC6 gene mutation (N110S) was a new mutation and pathogenic in the preliminary clinical work. The purpose of this study was to investigate the potential mechanism of mutation in TRPC6 (TRPC6-N110S) in the knock-in gene mouse model and in immortalized mouse podocytes (MPC5). Transmission electron microscopy was used to evaluate renal injury morphology. We measured 24-hour urinary albumin-to-creatinine ratios and major biochemical parameters such as serum albumin, urea nitrogen, and total cholesterol. The results of CCK-8 assay and apoptosis experiments showed that the TRPC6-N110S overexpression group had slower proliferative activity and increased apoptosis than the control group. FluO-3 assay revealed increased calcium influx in the TRPC6-N110S overexpression group. Podocin level was decreased in TRPC6-N110S group, while TRPC6 and desmin levels were increased in TRPC6-N110S group. The 24 h uACR at 6 weeks was significantly higher in the pure-zygotes group than in the WT and heterozygotes groups, and this difference was found at 8 and 10 weeks.TRPC6 levels showed no significant difference between homozygote and WT mice. Compared to homozygote group, expression of podocin and nephrin were increased in WT, but levels of desmin was decreased in WT. Our results suggest that this new mutation causes podocyte injury probably by enhancing calcium influx and podocyte apoptosis, accompanied by increased proteinuria and decreased expression of nephrin and podocin.